GSK files pazopanib for renal cancer after Phase III success
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has filed its new oral anti-angiogenic anticancer Armala (pazopanib) in the US and the EU for its first indication, advanced kidney cancer, after the drug met its primary endpoint of progression-free survival (PFS) in the first of its Phase III trials.